Spero Therapeutics Inc
NASDAQ:SPRO
Spero Therapeutics Inc
NASDAQ:SPRO
Price:
1.6 USD
-3.03%
Market Closed
Updated:
May 15, 2024
Balance Sheet
Balance Sheet Decomposition
Spero Therapeutics Inc
Spero Therapeutics Inc
| Current Assets | 131.2m |
| Cash & Short-Term Investments | 76.3m |
| Receivables | 50.7m |
| Other Current Assets | 4.2m |
| Non-Current Assets | 51.2m |
| PP&E | 4.2m |
| Other Non-Current Assets | 47m |
| Current Liabilities | 37.2m |
| Accounts Payable | 1.4m |
| Accrued Liabilities | 8.3m |
| Other Current Liabilities | 27.5m |
| Non-Current Liabilities | 38.3m |
| Other Non-Current Liabilities | 38.3m |
Balance Sheet
Spero Therapeutics Inc
Spero Therapeutics Inc
Currency: USD
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
6
|
10
|
87
|
34
|
30
|
85
|
113
|
109
|
76
|
|
| Cash Equivalents |
6
|
10
|
87
|
34
|
30
|
85
|
113
|
109
|
76
|
|
| Short-Term Investments |
0
|
0
|
0
|
81
|
52
|
42
|
34
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
3
|
1
|
9
|
6
|
3
|
1
|
51
|
|
| Other Current Assets |
0
|
1
|
2
|
8
|
5
|
6
|
9
|
3
|
4
|
|
| Total Current Assets |
6
|
12
|
92
|
124
|
95
|
139
|
158
|
114
|
131
|
|
| PP&E Net |
1
|
2
|
1
|
3
|
7
|
9
|
8
|
6
|
4
|
|
| PP&E Gross |
1
|
2
|
1
|
3
|
7
|
9
|
8
|
6
|
4
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
1
|
2
|
2
|
3
|
3
|
4
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
47
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
2
|
4
|
5
|
6
|
6
|
0
|
|
| Total Assets |
7
N/A
|
14
+92%
|
94
+578%
|
129
+38%
|
106
-18%
|
154
+45%
|
171
+11%
|
125
-27%
|
182
+46%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
2
|
1
|
4
|
4
|
4
|
1
|
1
|
1
|
1
|
|
| Accrued Liabilities |
1
|
3
|
4
|
8
|
23
|
13
|
16
|
11
|
8
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
4
|
3
|
0
|
1
|
0
|
0
|
2
|
10
|
28
|
|
| Total Current Liabilities |
6
|
7
|
8
|
12
|
27
|
14
|
19
|
22
|
37
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
48
|
0
|
0
|
|
| Minority Interest |
1
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
1
|
0
|
1
|
5
|
7
|
16
|
27
|
38
|
|
| Total Liabilities |
7
N/A
|
4
-49%
|
9
+147%
|
14
+52%
|
32
+133%
|
21
-32%
|
83
+287%
|
49
-41%
|
75
+54%
|
|
| Equity | ||||||||||
| Common Stock |
18
|
56
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
18
|
45
|
97
|
139
|
199
|
278
|
368
|
414
|
391
|
|
| Additional Paid In Capital |
0
|
0
|
181
|
254
|
274
|
410
|
456
|
490
|
498
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
0
N/A
|
10
+5 000%
|
85
+729%
|
116
+37%
|
75
-35%
|
132
+77%
|
88
-33%
|
76
-14%
|
107
+41%
|
|
| Total Liabilities & Equity |
7
N/A
|
14
+92%
|
94
+578%
|
129
+38%
|
106
-18%
|
154
+45%
|
171
+11%
|
125
-27%
|
182
+46%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
14
|
14
|
14
|
17
|
19
|
29
|
32
|
53
|
53
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
3
|
3
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
